Table 3.
Postoperative enzyme markers of liver injurya
| Comparison | Postoperative day | AST, MD (95% CI) | ALT MD (95% CI) |
|---|---|---|---|
| Dextrose vs. control74,75 | 1 | −107.20 (−1.53 to −0.83) | −123.3 (−182.47 to −64.13) |
| 5 | −89.7 (−133.04 to −6.36) | −191.0 (−243.15 to −138.85) | |
| Methylprednisolone vs. control54,59,67–69 | 2 | −117.0 (−221.03 to −12.97) | −125.0 (−239.48 to −10.52) |
| Trimetazidine vs. placebo70 | 1 | −29.0 (−56.92 to −1.08) | −30.0 (−59.50 to −0.50) |
| 3 | −20.0 (−39.69 to −0.31) | −19.0 (−37.71 to −0.29) | |
| 5 | −7.0 (−13.56 to −0.44) | −15.0 (−29.75 to −0.25) | |
| 7 | −8.0 (−15.37 to −0.63) | ||
| 10 | −5.0 (−9.90 to −0.10) | ||
| Sevoflurane vs. propofol56 | Peak levels | −254.18 (−450.59 to −57.77) | |
| Ulinastatin vs. gantaileb63 | AST on 3 ALT on 1, 3, 7 | Exact value not reported | Exact values not reported |
| Vitamin E vs. placeboc55 | 1 to 6 | Area under curve. Exact value not reported |
a
Only significant results are shown
b
The trial authors reported a significant difference between the groups but did not provide the exact numerical values
c
The trial authors reported a significant reduction in AST levels on days 1–6 postoperatively as measured by the area under the curve
AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; MD, mean difference